EPLUS SKIN TREATMENT SYSTEM

K113868 · Syneron, Ltd. · GEX · Jun 11, 2012 · General, Plastic Surgery

Device Facts

Record IDK113868
Device NameEPLUS SKIN TREATMENT SYSTEM
ApplicantSyneron, Ltd.
Product CodeGEX · General, Plastic Surgery
Decision DateJun 11, 2012
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 878.4810
Device ClassClass 2
AttributesTherapeutic

Intended Use

The ePlus Skin Treatment system is intended for dermatological procedures.

Device Story

ePlus Skin Treatment System is a multi-application dermatological device; delivers electromagnetic energy via system applicators. Inputs: electrical power; outputs: optical radiation (Laser or IPL in visible/near-IR range) and 1MHz RF current. Used in clinical settings by trained operators. Applicators include DS, DSL, LV, LVA, WRA, SR, SRA, AC, Sublative RF, and Sublime. Energy delivery targets skin tissue for hair reduction, vascular/pigmented lesion treatment, acne therapy, and skin resurfacing/wrinkle reduction. Benefits include non-invasive or ablative skin rejuvenation and lesion management. Clinical decision-making relies on operator selection of appropriate applicator based on patient skin type and condition.

Clinical Evidence

No clinical data provided. Safety and efficacy were established by reference to the clinical performance data of the predicate devices that utilize the same applicators.

Technological Characteristics

Multi-application system delivering optical radiation (Laser/IPL) and 1MHz RF current. Complies with IEC 60601-1 (safety), IEC 60601-2-2 (high frequency surgical equipment), IEC 60601-2-22 (laser equipment), IEC 60825-1 (laser safety), and IEC 60601-1-2 (EMC).

Indications for Use

Indicated for hair removal and permanent hair reduction (all skin types I-VI, including tanned skin); treatment of vascular lesions; non-invasive wrinkle treatment; treatment of superficial benign vascular and pigmented lesions (lentigines, freckles, telangiectasia, rosacea, poikiloderma, angioma, sun spots, age spots) on face, chest, hands, arms, or sporadic body areas; treatment of moderate inflammatory acne vulgaris; and dermatological procedures requiring skin ablation and resurfacing.

Regulatory Classification

Identification

(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image shows the logo for Syneron Medical LTD. The word "Syneron" is written in a stylized font, with the "S" being larger and more decorative than the other letters. Below the word "Syneron" is the text "Medical LTD". # 510(K) SUMMARY # ePlus Skin Treatment System 510(k) Number K113868 | Applicant's Name: | Syneron Medical Ltd. | |-------------------|-----------------------| | | Industrial Zone | | | Tavor Building | | | Yokneam Illit 20692 | | | Israel | | | Tel: (972)73-244-2200 | | | Fax: (972)73-244-2202 | | | | - Yoram Levy, Osite Contact Person: 31 Haavoda Street Binyamina, Israel 30500 Tel (972)4-638-8837; Fax (972)4-638-0510 Yoram@gsitemed.com Trade Name: ePlus Skin Treatment System December 27. 2011 Preparation Date: Name: Powered laser surgical instrument Classification: Product Code: GEX, OUH Regulation No: 21 CFR 878.4400, 21CFR 878.4810 Class: II Panel: General and Plastic Surgery #### Device Description: The ePlus skin treatment system is a multi-application system that provides a variety of skin treatments. The system combines Syneron's previously cleared Polaris, Aurora and eTwo treatment Systems and their applicators. The ePlus skin treatment system delivers two ranges of electromagnetic energy to the skin tissue through the system applicators: - Optical radiation through Laser or IPL (Intense Pulse Light) in 1. the visible & near-IR range. 2. RF current conducted through the tissue at 1MHz #### Intended Use Statement: The ePlus Skin Treatment system is intended for dermatological procedures. {1}------------------------------------------------ 113868 2/3 # Medical LTD meron The DS applicator is indicated for the removal of unwanted hair from skin types I-VI. and to effect stable long-term, or permanent, hair reduction*. The DSL applicator is indicated for hair removal, permanent hair reduction*. The applicator is intended for use on all skin types. (Fitzpatrick skin type I-VI), including tanned skin. The LV applicator is indicated for treatment of vascular lesions. The LVA applicator is indicated for treatment of vascular lesions. The WRA applicator is indicated for non invasive wrinkles treatment. The SR applicator is intended for superficial benign vascular and pigmented lesion treatment such as: lentigines. freckles. telangiectasia. rosacea. poikiloderma, angioma, sun spots and age spots. The SR treatment may be performed on body areas such as the face. chest. hands and arms. It can be also performed on sporadic lesions anywhere on the body. The SRA applicator is intended for superficial benign vascular and pigmented lesion treatment such as: lentigines. freckles. telangiectasia. rosacea. poikiloderma. angioma, sun spots and age spots. The SRA treatment may be performed on body areas such as the face, chest, hands and arms. It can be also performed on sporadic lesions anywhere on the body. The AC applicator is indicated for the treatment of moderate inflammatory acne vulgaries. The Sublative RF applicator is indicated for Dermatological procedures requiring ablation and resurfacing of the skin, and for the treatment of facial wrinkles. The Sublime applicator is indicated for non invasive wrinkles treatment. * Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regimen Substantial equivalence to the following predicate devices is Predicate Devices: claimed: {2}------------------------------------------------ Image /page/2/Picture/0 description: The image contains the word "Syneron" in a stylized font. The word is written in black ink and appears to be part of a logo or brand name. Below the word "Syneron" is the word "Medical LTD". 113 867. 7/3 # Medical LTD | Syneron Device Name | 510k No | Date of Clearance | |-------------------------------|---------|--------------------| | Polaris DS / Comet Applicator | K041959 | November 8, 2004 | | Polaris LV | K030186 | April 14, 2003 | | Polaris WR | K031671 | December 1, 2003 | | Aurora SR | K031993 | August 1, 2003 | | AC applicator, Aurora AC | K032514 | January 27, 2004 | | Aurora DS, DS applicator | K050796 | April 12, 2005 | | Aurora SR and SRA applicator | K050452 | March 9, 2005 | | Polaris LV, LVA applicator | K052324 | September 14, 2005 | | eTwo Skin Treatment System | K110672 | October 03, 2011 | #### Performance Standards: #### ePlus Skin Treatment System complies with: - . IEC 60601-1 : "Medical Electrical Equipment" Part 1: "General requirements for safety" - IEC 60601-2-2: "Medical Electrical Equipment" Part 2: "Particular . requirements for the safety of high frequency surgical equipment" (2006) - IEC 60601-2-22 : "Medical Electrical Equipment" Part 2: . ● "Particular requirements for the safety of diagnostic and therapeutic laser equipment" (1995) - IEC60825-1 : Safety of laser products Part 1: "Equipment . classification, requirements and user's guide" (2007) - IEC 60601-1-2 Ed. 2.1 (2004): medical electrical equipment: Part . 1-2 collateral standard: Electromagnetic compatibility Requirements and tests" A detailed description appears in Section 13. #### Summary of Clinical Performance Data: The safety and efficacy of the ePlus Skin Treatment System was evaluated in the clearance process of the predicate devices that use the same applicators that are part of this device. Syneron believes that clinical data is not required to determine the safety and efficacy of the ePlus Skin Treatment System since the intended use and technical performance of ePlus and its applicators are equivalent to the predicate devices. {3}------------------------------------------------ ## DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three lines representing its wings and body. The eagle is positioned to the right of a circular arrangement of text that reads "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA". #### Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 JUN 1 1 2012 - Syneron. Ltd Yo Osite Yoram Levy 31 Haavoda Street Binyamina, Israel 30500 Re: K113868 Trade/Device Name: ePlus Skin Treatment System Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: GEX Dated: June 01, 2012 Received: June 05, 2012 Dear Yoram Levy: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {4}------------------------------------------------ #### Page 2 - Yoram Levy Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours, Mark Millikan Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ # Ineron Medical LTD # INDICATIONS FOR USE STATEMENT #### 510(k) Number (if known): K113868 Device Name: ePlus Skin Treatment System Indications for Use: The ePlus Skin Treatment system is intended for dermatological procedures. The DS applicator is indicated for the removal of unwanted hair from skin types I-VI, and to effect stable long-term, or permanent, hair reduction*. The DSL applicator is indicated for hair removal. permanent hair reduction*. The applicator is intended for use on all skin types, (Fitzpatrick skin type I-VI), including tanned skin. The LV applicator is indicated for treatment of vascular lesions. The LVA applicator is indicated for treatment of vascular lesions. The WRA applicator is indicated for non invasive wrinkles treatment. The SR applicator is intended for superficial benign vascular and pigmented lesion treatment such as: lentigines, freckles, telangiectasia, rosacea, poikiloderma, angioma, sun spots and age spots. The SR treatment may be performed on body areas such as the face, chest, hands and arms. It can be also performed on sporadic lesions anywhere on the body. The SRA applicator is intended for superficial benign vascular and pigmented lesion treatment such as: lentigines. freckles, telangiectasia, rosacea, poikiloderma, angioma, sun spots and age spots. The SRA treatment may be performed on body areas such as the face, chest, hands and arms. It can be also performed on sporadic lesions anywhere on the body. The AC applicator is indicated for the treatment of moderate inflammatory acne vulgaries. ## ePlus Skin Treatment System - 510(k) Notification Neil RPDoplin for mxm (Division Sign-Off) Division of Surgical, Orthopedic, and Restorative Devices 510(k) Number K113868 {6}------------------------------------------------ Image /page/6/Picture/0 description: The image shows the logo for Syneron Medical LTD. The word "Syneron" is written in a stylized font, with the "S" having a unique design. Below "Syneron" is the text "Medical LTD" in a standard, bold font. The logo appears to be for a medical company. The Sublative RF applicator is indicated for Dermatological procedures requiring ablation and resurfacing of the skin, and for the treatment of facial wrinkles. The Sublime applicator is indicated for non invasive wrinkles treatment. *Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6. 9, and 12 months after the completion of a treatment regimen Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE -CONTINUE ON ANOTHER PAGE IF NEEDED). Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-off), Division of General, Restorative and Neurological Devices 510(k) Number Neihroplen Sir mxm (Division Sign-Division of Surgical, Orthopedic, and Restorative Devices 510(k) Number K113868
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%